AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$44.55
+$1.06 (+2.43%) 4:00 PM ET
Pre-market$44.03
−$0.52 (−1.16%) 4:52 PM ET
Prev closePrevC$43.49
OpenOpen$44.30
Day highHigh$44.55
Day lowLow$43.43
VolumeVol546,795
Avg volAvgVol626,443
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$3.37B
P/E ratio
59.39
FY Revenue
$677.56M
EPS
0.75
Gross Margin
88.54%
Sector
Healthcare
AI report sections
BULLISH
KNSA
Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals shows a strong upward price trend near its 52-week high supported by bullish technical signals. Fundamentally, the company exhibits double‑digit revenue growth, sharply improved profitability, and healthy free cash flow generation with a solid balance sheet. Offsetting this, elevated days-to-cover on short interest and a momentum-driven, late-cycle price position introduce risk of volatility and pullbacks.
AI summarized at 2:27 PM ET, 2025-12-22
AI summary scores
INTRADAY:72SWING:78LONG:74
Volume vs average
Intraday (cumulative)
+7% (Above avg)
Vol/Avg: 1.07×
RSI
47.33(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
+0.03 (Strong)
MACD: 0.10 Signal: 0.08
Short-Term
-0.30 (Weak)
MACD: 0.56 Signal: 0.86
Long-Term
-0.10 (Weak)
MACD: 1.13 Signal: 1.23
Intraday trend score
79.52
LOW52.52HIGH80.52
Latest news
KNSA•12 articles•Positive: 6Neutral: 1Negative: 0
PositiveGlobeNewswire Inc.• Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
Kiniksa Pharmaceuticals received FDA Orphan Drug Designation for KPL-387, a monoclonal antibody targeting pericarditis treatment, with potential for monthly subcutaneous self-injection.
Company received FDA Orphan Drug Designation, indicating promising progress in developing a novel treatment for a rare disease
PositiveGlobeNewswire Inc.• N/A
Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis
Kiniksa Pharmaceuticals announces plans for a Phase 2/3 clinical trial of its drug KPL-387 in recurrent pericarditis, with the trial expected to initiate in mid-2025 and Phase 2 data expected in the second half of 2026.
The article outlines Kiniksa's plans for a Phase 2/3 clinical trial of its drug KPL-387 in recurrent pericarditis, which suggests the company is making progress in developing a potential treatment for this condition.
PositiveGlobeNewswire Inc.• N/A
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
Kiniksa Pharmaceuticals announced that country star Carly Pearce has joined their Life DisRPted campaign to raise awareness for recurrent pericarditis. The company also reported strong Q1 2025 financial results for their ARCALYST product, with net product revenue of $137.8 million and increased 2025 revenue guidance.
The article highlights Kiniksa's successful Q1 2025 financial results for ARCALYST, with strong revenue growth and increased guidance. Additionally, the company's partnership with Carly Pearce to raise awareness for recurrent pericarditis indicates positive momentum in their business and product portfolio.
PositiveThe Motley Fool• Keith Speights
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
The article highlights three healthcare stocks that are considered good investments right now: AbbVie, Vertex Pharmaceuticals, and Kiniksa Pharmaceuticals. It discusses the growth prospects and financial metrics of these companies.
Kiniksa's drug Arcalyst, approved for treating recurrent pericarditis, has seen a significant increase in sales and has a large market opportunity. The company also has a promising pipeline of other programs.
NeutralGlobeNewswire Inc.• N/A
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
Kiniksa Pharmaceuticals, a biopharmaceutical company, announced that it will host a conference call on February 25, 2025, to report its fourth quarter and full year 2024 financial results and recent portfolio execution.
The article provides a factual update on Kiniksa Pharmaceuticals' upcoming financial results announcement, without any explicit positive or negative sentiment.
PositiveGlobeNewswire Inc.• Delveinsight
Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight
The article discusses the evolving landscape of rare cardiovascular diseases, including Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy. It highlights the challenges in diagnosis and treatment, as well as the growing market size and pipeline of new therapies for these conditions.
The article mentions Mavrilimumab, a pipeline therapy for Giant-Cell Arteritis, being developed by CSL/Kiniksa Pharmaceuticals, indicating their involvement in the rare disease market.
PositiveGlobeNewswire Inc.• Delveinsight
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight
The urticaria pipeline is rapidly expanding, with over 20 leading companies developing 25+ new treatments to address the rising prevalence of the condition. Advances in biologic therapies and a strong R&D pipeline are driving progress, while improved healthcare infrastructure and digital innovations enhance patient access and outcomes.
Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
HAMILTON, Bermuda, June 04, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 8:40 a.m. Eastern Time.
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on Tuesday, May 14, 2024 at 10:40 a.m. Pacific Time (1:40 p.m. Eastern Time).
KNSACalendar of Events
UnknownZacks Investment Research• Zacks Equity Research
Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of -78.57% and 4.05%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $370 - $390 million –– Abiprubart Phase 2b trial in Sjögren’s Disease planned to initiate in 2H 2024 –– Current operating plan expected to remain cash flow positive on an annual basis – – Conference call and webcast scheduled for 8:30 am ET today –
KNSAEarnings Releases and Operating Results
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
